Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case–control studies
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths. METHODS: Within the Quebec Pregnancy Cohort (1998-2015), we identified women exposed to low- (≤ 150 mg) and high-dose (> 150 mg) fluconazole, and women who were not exposed. For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected using an incidence density sampling method matched on gestational age at diagnosis of spontaneous abortion or stillbirth (index date) and the year of the last menstrual period. For cases of major congenital malformation, we considered all liveborn babies as controls. Generalized estimation equation models were used to analyze the 3 main outcomes separately. RESULTS: Within a cohort of 441 949 pregnancies, 320 868 pregnancies were included in the analyses of spontaneous abortions, 226 599 of major congenital malformations and 7832 of stillbirths. Most (69.5%) women exposed to fluconazole in pregnancy received the common single therapeutic dose of 150 mg (low dose); the remainder received a dose of > 150 mg (high dose). Use of oral fluconazole during early pregnancy was associated with an increased risk of spontaneous abortion compared with no exposure (adjusted odds ratio [OR] for 345 cases exposed to low-dose treatment 2.23, 95% confidence interval [CI] 1.96-2.54; adjusted OR for 249 cases exposed to high-dose treatment 3.20, 95% CI 2.73-3.75). Exposure to fluconazole during the first trimester did not increase the risk of overall major congenital malformations; however, exposure to a high dose during the first trimester was associated with an increased risk of cardiac septal closure anomalies (adjusted OR 1.81, 95% CI 1.04-3.14; 13 exposed cases) compared with no exposure. No association was found between exposure to fluconazole during pregnancy and the risk of stillbirth. INTERPRETATION: Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1993 Sexually Transmitted Diseases Treatment Guidelines
(1994) · Journal of School Health · doi:10.1111/j.1746-1561.1994.tb03287.x · Cited by 918
Malformation syndromes caused by disorders of cholesterol synthesis
Porter, F. D., & Herman, G. E. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r009548 · Cited by 473
Fluconazole-induced congenital anomalies in three infants
Pursley, T. J., Blomquist, I. K., Abraham, J., Andersen, H. F., & Bartley, J. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.336 · Cited by 246
Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy
Cotch, M. F., Hillier, S. L., Gibbs, R. S., & Eschenbach, D. A. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80028-8 · Cited by 198
Adachi, M., Tachibana, K., Asakura, Y., Yamamoto, T., Hanaki, K., & Oka, A. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30169 · Cited by 110
Keber, R., Motaln, H., Wagner, K. D., Debeljak, N., Rassoulzadegan, M., Ačimovič, J., Rozman, D., & Horvat, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253245 · Cited by 102
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Gupta, A. K., Stec, N., Summerbell, R. C., Shear, N. H., Piguet, V., Tosti, A., & Piraccini, B. M. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16394 · Cited by 289
Nyirjesy, P., Brookhart, C., Lazenby, G., Schwebke, J., & Sobel, J. D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1057 · Cited by 149
Schwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., Chappell, B. T., Weinstein, D. L., Moffett, A. H., Azie, N. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab750 · Cited by 82
Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46
Metadata
- Authors
- Bérard, A., Sheehy, O., Zhao, J.-P., Gorgui, J., Bernatsky, S., de Moura, C. S., & Abrahamowicz, M.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Impact Inc.
- Published
- 2019-02-18
- Volume
- 191
- Issue
- 7
- Pages
- E179-E187
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2912782996
- Cited by
- 61
- References
- 6
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.